London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
oh, and he's back in my filter bin where he belongs. You should all consider doing that for when he reappears.
OK folks, it's more than 24 hours since I invited dumb to explain how he/she got 18% 'advantage' for patients taking Budesonide over those not taking it for hospitalisation. He is of course WRONG and it is actually 1.8%. I just wanted to clear that up in case anyone was wondering. (tumbleweed.... ?). It's a shame because I was looking forward to being 'owned' by the great man (woman). I was never going to let it go once he said I didn't understand percentages. I suspect I have a slight advantage over him.
I’m a respiratory nurse in primary health care. All our COPD and Asthma patients are taking inhaled corticosteroids in either single form or combined with a bronchodilator. Those who got Covid have done really well. This surprised me so there is something in this .
well gosh, I am really disappointed dumb.
We literally can't shut you up and then you disappear when you are called out.
I'm wondering if you want to school me and others on percentages? I mean you've said we 'don't understand them' and I've failed the maths test'.
Come on, dazzle me. You are probably wondering what you are up against? Has he really only got a gcse or not?
dumbpunter, you are wrong.
I mean, I got a grade C gcse maths, what did you get?
This is from a piece of fluff bbc report. Even the people who gave them the information admit there is little substance to the 'trial'.
Even the trial groups aren't the same size. Why is that?
2.1% benefit of budesonide over usual care in hospitalisation or death
COVID-19 related hospitalizations/deaths in the budesonide group vs 100/968 (10.3%) in the usual care group (estimated percentage benefit, 2.1%
[95% BCI -0.7% - 4.8%], probability of superiority 0.928)
I think I’d prefer Synairgen
I suspect when they expand trials to more risky patients they may come a cropper. Corticosteroids can suppress the immune response if given too early it could cause more harm than good.
SNG001 suppresses the virus so is a much safer bet for early use.
This is a cheap anti-inflammatory that masks Covid symptoms, as the trial shows people self reported they felt better on average 3 days quicker. As a treatment for symptoms its a no brainer to give people. Cheap, easy to use and used worldwide. In America its known as Pulmicort.
From trial
'Based on the interim analysis using the latest data from 25th March 2021, the results showed the estimated median time to self-reported recovery for inhaled budesonide was 3.011 days shorter compared to usual care (95% Bayesian credible interval 1.134 to 5.410 days)'
However it is not a game changer in my view as some of the media reports say.
* The trial was not a blinded placebo controlled trial, patients in the trial knew they were in the drug group or SOC group. Obviously this can influence results and have bias considering participants self reported results.
* The drug is not an anti-viral and as expected didnt do too much in the way of preventing hospitalisation.
From trial
'Among patients who had completed all 28 days of study follow up by 25th March 2021, 8.5% (59/692) in the budesonide group were hospitalised with COVID-19 compared with 10.3% (100/968) in the usual care group (estimated percentage benefit, 2.1% [95% BCI -0.7% – 4.8%], probability of superiority 0.928). Since fewer than expected people were admitted to hospital in the trial, and with COVID-19 cases and hospitalisations continuing to drop in the UK, it is not clear from this interim analysis whether budesonide reduces hospitalisations.'
So its pretty clear this drug looks to reduce symptoms and people self report they feel better quicker in people who can mount a good normal immune response to Covid.
However minimal reduction in hospitalisation as the drug doesn't do anything to stop the virus (as expected its not an anti-viral) and with the 95% CIs we can see its not conclusive which the trial researchers admit. So people who for what ever reason develop moderate/severe Covid will still likely end up going into hospital.
The boy you've been saying 1.30 since last week are you just saying that so u can buy more at that price
that's good because 1% is closer.
Hardly a controlled trial is it? Statistical significance?
Even 9 out of 10 cats prefer Whiskers.
Even if this stuff is 1% effective, it is great news, as it will save *some* lives. More than SNG. At a cost that, even at 1% effectiveness, is less than half of what Ritchie is looking for at 89% effectiveness for £3k.
Of course, this bude-whats-its-name thing is pretty much irrelevant to sng, as UK has not been our target market for quite a while now.
well, he's wrong.
I'm not saying that's correct way to calculate it, I'm saying that's how he got 18% =)
Actually similar to what I expect our home trials to replicate! Definite help but limited. This treatment is cheaper
Maybe this market has now gone.
incorrect. Please stay after class.
8.5/10.3
We drop to 130 tomorrow
Until some form of news. And I imagine the board are getting nervous that the window is closing! This headline coverage is what we needed
18%? Please explain.
But the difference in reducing hospital admissions is tiny (although it probably does do something). These results are nowhere near in the league of what SNG001 was able to do in the intial study.
“ Researchers say that since fewer people than expected were admitted to hospital in the trial, and with cases and admissions to hospital continuing to drop in the UK, the interim analysis – published as a pre-print – cannot suggest whether budesonide reduces hospital admissions”
Sounds pretty.....inconclusive
https://www.theguardian.com/world/2021/feb/10/asthma-drug-budesonide-may-reduce-risk-severe-covid-if-taken-early-study
If the BBC is referring to Budesonide this is what I posted Saturday
For those interested Budesonide a good article in the Guardian and the next stage P3 the Oxford Principle trial which includes over 65s with co morbidities .The P2 which are not yet peer reviewed describes the benefits of the anti-inflammatory effect Budesonide but “may “ have an effect on viral replications. Does not stand up to our drug I think a lot more needs to be done before it becomes the full Monty but there again, they have the Oxford connection
Agreed, I’ve just done the same. Another 5k top up.
Fruits - also stopped early, partly because they were struggling to recruit
Fruitsandveg
When do you envisage Activ2 across the pond completing?